[ad_1]
Novavax, the American biotechnology company, announced on Thursday that it has begun the third phase of clinical trials in Great Britain for its vaccine against Covid-19, making it the eleventh experimental vaccine in the world to reach this final stage.
The company said that 10,000 volunteers between the ages of 18 and 84 will participate in these experiences.
“Due to the current high level of transmission of SARS-Cove-2, and given that this level will likely remain high in the UK, we are optimistic that this is the third phase of testing,” the statement to Gregory Glenn quoted as saying, director of research and development of the company. The core clinic will benefit from a rapid volunteer process and a short-term evaluation of the efficacy of the vaccine will be provided.
It is the eleventh vaccine in the world to enter the final stage of clinical trials, involving tens of thousands of volunteers, which are usually divided into two equal parts: half receive a placebo vaccine and the other half receive the experimental vaccine .
The most advanced Western project on the road to producing a deadly virus vaccine is the experimental vaccine developed by Oxford partner AstraZeneca, and two other vaccines developed by Pfizer and Moderna.
In parallel, similar projects are being carried out in China and Russia.
Novavax is one of six companies that received hundreds of millions of dollars in funding from the US federal government to produce a vaccine against the emerging coronavirus, and it is the fifth whose experimental vaccine enters phase three.
The company has raised more than $ 1.6 billion in public funds from the United States to produce 100 million doses of the vaccine.
Follow the health statement through Google News
